The median duration between the first anti-PD-1 antibody injection and the onset of nivolumab-related ICI-T1DM was 121 days (range 71–190 days).[3] In this case, the duration was 96 days, which is approximately consistent with the median duration. Here, PDCD1 is linked to type 1 diabetes mellitus.